-
-
-
-
-
-
-
Oppenheimer Reiterates Nurix (NRIX) at Outperform, 'see significant upside potential for NRIX'
-
-
-
-
-
-
-
Nurix Therapeutics partners with Roche on BTK degrader drug deal
-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Nurix (NRIX)
-
-
-
-
-
-
-
Nurix (NRIX) PT Raised to $35 at Piper Sandler
-
-
-
-
-
-
-
Morgan Stanley Upgrades Nurix (NRIX) to Overweight
-
-
-
-
-
-
-
Nurix (NRIX) PT Raised to $29 at RBC Capital
-
-
-
-
-
-
-
Nurix (NRIX) PT Lowered to $12 at Leerink Partners
-
431,483 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

